Clinical Trials Browser

Mast Cell Activation Disorders × Myeloid × Clear all

Mast Cell Activation Disorders, Mastocytosis

NCT06466889 2024-06-26

MastoR

Recruiting

400 enrolled

Myeloid

Mast Cell Activation Disorders, Mastocytosis

NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Phase 1 Completed

282 enrolled

CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

NCT04615663 2020-11-04

MCD&BuDi

Unknown

200 enrolled

Myeloid

Mast Cell Activation Disorders, Mastocytosis

NCT00336076 2016-11-07

Molecular Mechanisms and Diagnosis of Mastocytosis

Completed

136 enrolled

Myeloid

Mast Cell Activation Disorders, Anaphylaxis, Mastocytosis, Piebaldism

NCT01297777 2016-08-29

Imatinib in KIT-negative Systemic Mastocytosis

Phase 4 Completed

10 enrolled

Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

NCT01602939 2016-08-29

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Phase 2/3 Unknown

10 enrolled

Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Clinical Trials

DATAMAST

MastoR

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

MCD&BuDi

Molecular Mechanisms and Diagnosis of Mastocytosis

Imatinib in KIT-negative Systemic Mastocytosis

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis